Cullinan Therapeutics
Jennifer Michaelson is an accomplished biotechnology executive with extensive experience in the fields of oncology and therapeutics. Currently serving as Chief Scientific Officer and Chief Development Officer at Cullinan Oncology, Jennifer has held prominent roles such as Vice President of Preclinical Research and Early Development, and Executive Program Leader at Jounce Therapeutics. Additionally, Jennifer has contributed to Third Rock Ventures as Head of Biologics for Celsius Therapeutics and served as a consultant for Jounce Therapeutics. Earlier in Jennifer’s career, significant positions at Biogen Idec included Principal Scientist and Senior Scientist. Jennifer’s educational background includes a medical degree from Harvard Medical School and a degree from Albert Einstein College of Medicine.
This person is not in the org chart
This person is not in any teams
Cullinan Therapeutics
1 followers
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.